690
R. Kaspera et al. / Biochemical Pharmacology 82 (2011) 681–691
[22] Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, et al.
Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xeno-
biotic oxidations catalyzed by 12 recombinant human cytochrome P450s
expressed in membranes of Escherichia coli. Protein Expr Purif
2002;24:329–37.
microsomes, likely due to an inhibitory effect of cytochrome b5.
The in vivo affect of CYP2C8*3 will most likely be substrate
dependent as well.
[23] Locuson CW, Wienkers LC, Jones JP, Tracy TS. CYP2C9 protein interactions with
cytochrome b(5): effects on the coupling of catalysis. Drug Metab Dispos
2007;35:1174–81.
Acknowledgement
[24] Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ.
Polymorphism in CYP2C8 is associated with reduced plasma concentrations
of repaglinide. Clin Pharmacol Ther 2003;74:380–7.
The authors wish to thank Professor William M. Atkins for his
critical evaluation of this manuscript and insightful comments.
[25] Porter TD, Wilson TE, Kasper CB. Expression of a functional 78 000 dalton
mammalian flavoprotein, NADPH-cytochrome P-450 oxidoreductase, in
Escherichia coli. Arch Biochem Biophys 1987;254:353–67.
Appendix A. Supplementary data
[26] Holmans PL, Shet MS, Martin-Wixtrom CA, Fisher CW, Estabrook RW. The
high-level expression in Escherichia coli of the membrane-bound form of
human and rat cytochrome b5 and studies on their mechanism of function.
Arch Biochem Biophys 1994;312:554–65.
Supplementary data associated with this article can be found, in
[27] Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD,
et al. Measurement of protein using bicinchoninic acid. Anal Biochem
1985;150:76–85.
References
[28] Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I.
Evidence for its hemoprotein nature. J Biol Chem 1964;239:2370–8.
[29] Cheesman MJ, Baer BR, Zheng YM, Gillam EM, Rettie AE. Rabbit CYP4B1
engineered for high-level expression in Escherichia coli: ligand stabilization
and processing of the N-terminus and heme prosthetic group. Arch Biochem
Biophys 2003;416:17–24.
[30] Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Charac-
terization of interintestinal and intraintestinal variations in human CYP3A-
dependent metabolism. J Pharmacol Exp Ther 1997;283:1552–62.
[31] Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the
Folin phenol reagent. J Biol Chem 1951;193:265–75.
[32] Naraharisetti SB, Lin YS, Rieder MJ, Marciante KD, Psaty BM, Thummel KE, et al.
Human liver expression of CYP2C8: gender, age, and genotype effects. Drug
Metab Dispos 2010;38:889–93.
[33] Nakano M, Kelly EJ, Rettie AE. Expression and characterization of CYP4V2 as a
fatty acid omega-hydroxylase. Drug Metab Dispos 2009;37:2119–22.
[34] Kelley RW, Reed JR, Backes WL. Effects of ionic strength on the functional
interactions between CYP2B4 and CYP1A2. Biochemistry 2005;44:2632–
41.
[1] Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual
variations in human liver cytochrome P-450 enzymes involved in the oxida-
tion of drugs, carcinogens and toxic chemicals: studies with liver micro-
somes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:
414–23.
[2] Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report
summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab
Rev 1997;29:413–580.
[3] Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmaco-
genetics, and clinical relevance. Clin Pharmacol Ther 2005;77:341–52.
[4] Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT. Gemfibrozil
markedly increases the plasma concentrations of montelukast: a previously
unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Phar-
macol Ther 2010;88:223–30.
[5] Kaspera R, Totah RA. Epoxyeicosatrienoic acids: formation, metabolism and
potential role in tissue physiology and pathophysiology. Expert Opin Drug
Metab Toxicol 2009;5:757–71.
[6] Thatcher JE, Zelter A, Isoherranen N. The relative importance of CYP26A1 in
hepatic clearance of all-trans retinoic acid. Biochem Pharmacol 2010;80:
903–12.
[7] Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al.
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer
drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:
597–607.
[35] Yasukochi Y, Masters BS. Some properties of a detergent-solubilized NADPH-
cytochrome c(cytochrome P-450) reductase purified by biospecific affinity
chromatography. J Biol Chem 1976;251:5337–44.
[36] Huang W, Lin YS, McConn 2nd DJ, Calamia JC, Totah RA, Isoherranen N, et al.
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
Drug Metab Dispos 2004;32:1434–45.
[8] Kaspera R, Naraharisetti SB, Tamraz B, Sahele T, Cheesman MJ, Kwok P-Y, et al.
Cerivastatin in vitro metabolism by CYP2C8 variants found in patients
experiencing rhabdomyolysis. Pharmacogen Genom 2010;20:619–29.
[9] Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of
clinical studies. Pharmacogenomics 2009;10:1489–510.
[10] Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine
metabolism is impaired by common polymorphisms in CYP2C8: implications
for malaria treatment in Africa. Clin Pharmacol Ther 2007;82:197–203.
[11] Gao Y, Liu D, Wang H, Zhu J, Chen C. Functional characterization of five CYP2C8
variants and prediction of CYP2C8 genotype-dependent effects on in vitro and
in vivo drug–drug interactions. Xenobiotica 2010;40:467–75.
[37] Bordoli L, Kiefer F, Arnold K, Benkert P, Battey J, Schwede T. Protein
structure homology modeling using SWISS-MODEL workspace. Nat Protoc
2009;4:1–13.
[38] Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nano-
systems: application to microtubules and the ribosome. Proc Natl Acad Sci U S
A 2001;98:10037–41.
[39] Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol
Graph 1996;14(33-8):27–8.
[40] Kuzmic P. Program DYNAFIT for the analysis of enzyme kinetic data: applica-
tion to HIV proteinase. Anal Biochem 1996;237:260–73.
[41] Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF. Determi-
nants of cytochrome P450 2C8 substrate binding structures of complexes with
montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem
2008;283:17227–3.
[12] Soyama A, Hanioka N, Saito Y, Murayama N, Ando M, Ozawa S, et al. Amio-
darone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8
P404A. Pharmacol Toxicol 2002;91:174–8.
[13] Smith HE, Jones 3rd JP, Kalhorn TF, Farin FM, Stapleton PL, Davis CL, et al. Role
of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced
chronic kidney disease. Pharmacogenet Genomics 2008;18:943–53.
[14] Rowbotham SE, Boddy AV, Redfern CP, Veal GJ, Daly AK. Relevance of non-
synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel
hydroxylation. Drug Metab Dispos 2010;38:1261–6.
[15] Parikh A, Guengerich FP. Expression, purification, and characterization of a
catalytically active human cytochrome P450 1A2:rat NADPH-cytochrome
P450 reductase fusion protein. Protein Expr Purif 1997;9:346–54.
[16] Zhang H, Myshkin E, Waskell L. Role of cytochrome b5 in catalysis by cyto-
chrome P450 2B4. Biochem Biophys Res Commun 2005;338:499–506.
[17] Schenkman JB, Jansson I. The many roles of cytochrome b5. Pharmacol Ther
2003;97:139–52.
[42] Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, et al. Co-regulation
of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam
metabolism. Mol Pharmacol 2002;62:162–72.
[43] Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, Green-
blatt DJ. Comparison between cytochrome P450 (CYP) content and relative
activity approaches to scaling from cDNA-expressed CYPs to human liver
microsomes: ratios of accessory proteins as sources of discrepancies between
the approaches. Drug Metab Dispos 2000;28:1493–504.
[44] Cryle MJ, De Voss JJ. The role of the conserved threonine in P450 BM3 oxygen
activation: substrate-determined hydroxylation activity of the Thr268Ala
mutant. Chembiochem 2008;9:261–6.
[45] Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities.
Drug Metab Dispos 2004;32:647–60.
[18] Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ.
Characterization of rat and human liver microsomal cytochrome P-450 forms
involved in nifedipine oxidation, a prototype for genetic polymorphism in
oxidative drug metabolism. J Biol Chem 1986;261:5051–60.
[46] Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450
enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin
Pharmacol 1999;48:424–32.
[47] McLaughlin LA, Ronseaux S, Finn RD, Henderson CJ, Roland Wolf C. Deletion of
microsomal cytochrome b5 profoundly affects hepatic and extrahepatic drug
metabolism. Mol Pharmacol 2010;78:269–78.
[19] Zhang H, Im SC, Waskell L. Cytochrome b5 increases the rate of product
formation by cytochrome P450 2B4 and competes with cytochrome P450
reductase for
a binding site on cytochrome P450 2B4. J Biol Chem
[48] Finn RD, McLaughlin LA, Ronseaux S, Rosewell I, Houston JB, Henderson CJ,
et al. Defining the in Vivo Role for cytochrome b5 in cytochrome P450 function
through the conditional hepatic deletion of microsomal cytochrome b5. J Biol
Chem 2008;283:31385–93.
2007;282:29766–7.
[20] Soucek P. Expression of cytochrome P450 2A6 in Escherichia coli: purification,
spectral and catalytic characterization, and preparation of polyclonal anti-
bodies. Arch Biochem Biophys 1999;370:190–200.
[49] Sandee D, Morrissey K, Agrawal V, Tam HK, Kramer MA, Tracy TS, et al. Effects
of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in
vitro. Pharmacogenet Genomics 2010;20:677–86.
[21] Locuson CW, Gannett PM, Tracy TS. Heteroactivator effects on the coupling
and spin state equilibrium of CYP2C9. Arch Biochem Biophys 2006;449:
115–29.